Monday, 24 Feb 2020

You are here

Rinvoq (upadacitinib) Effective in Psoriatic Arthritis

Yesterday, AbbVie reported the top-line study results showing the efficacy of Rinvoq (upadacitinib - UPAD) adult patients with active psoriatic arthritis who previously had an inadequate response to a biologic DMARD.

The SELECT-PsA 2 trial was a Phase 3, multicenter, study of active PsA, not responding to bDMARDs, who were randomized to either placebo (PBO) or UPAD (15 mg or 30 mg) once daily for 24 weeks.  The primary endpoint was the number of ACR20 responders at week 12.  ACR20 and other responses are shown below:

MeasureUPAD 15/dUPAD 30/dPBOp Value
N =211218212-

ACR 20 (Wk 12)

576424p<0.0001

ACR 50 (Wk 12)

32385p<0.0001

ACR 70 (Wk 12)

9170.5%p<0.0001

PASI 75 (Wk 16)

525716p<0.0001

MDA (Wk 24)

25293p<0.0001

 The safety profile of RINVOQ was consistent with that of previous studies across indications, with no new safety risks detected.  Through week 24, serious infections occurred in 0.5/2.8 percent of patients in the 15/30 mg UPAD groups, respectively, compared to 0.5 percent in the PBO group.

There was one pulmonary embolism reported in the 15 mg UPAD group and none in the 30 mg and placebo groups. There was one non-fatal adjudicated major adverse cardiovascular event (MACE) in the 15 mg UPAD group (acute myocardial infarction) and no MACE in the 30 mg and placebo groups. One death was reported in a patient receiving placebo (motor vehicle accident).

 

Full results from the SELECT-PsA 2 study will be presented at a future medical meeting. 

Rinvoq (upadacitinib) was FDA approved (earlier in 2019) for use in moderately to severely active rheumatoid arthritis.

There are other Phase 3 trials of UPAD in progress in other disorders, including psoriatic arthritis, Crohn's disease, atopic dermatitis, ulcerative colitis, giant cell arteritis, and ankylosing spondylitis.

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

No Cancer Increase in Psoriatic Arthritis or with Biologics in Psoriasis

JAMA Dermatology reports that psoriasis is associated with a slightly increased risk of cancer, particularly keratinocyte cancer and lymphomas.

A systematic review and meta-analysis of 112 studies including more than 2 million patients, also shows no increase in when psoriasis is treated with biologic agents, nor was psoriatic arthritis associated with an increased risk of cancer.   

Bimekizumab Effective in Active Psoriatic Arthritis

Interleukin 17 IIL-17) is important in the pathogenesis of psoriatic disease, with most current approaches targeting IL-17A. Now there is a noveal approach showing that dual neutralisation of IL-17A and IL-17F in psoriatic arthritis arthritis patients results in clinically significant improvement.

Upadacitinib Effective in Phase 3 Psoriatic Arthritis Study

Abbvie has announced top line results of their SELECT-PSA trial of upadacitinib (UPA), wherein both the 15 and 30 mg doses met the primary endpoint of ACR20 response at week 12 and demonstrated radiographic inhibition at week 24.

Which Biologics are Best in Psoriasis

A metanalysis of phase II, III and IV trials in moderate to severe plaque psoriasis suggests comparative efficacy biologic treatments, but that that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were shown to have the past skin (PASI) response rates.

Taltz Shines in Non-Radiographic Axial Spondyloarthritis

Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA). Lancet has published the results of the COAST-X study showing that ixekizumab was effective in patients with non-radiographic axial spondyloarthritis.